Dr. José Luis Del Pozo: The Fight Against Gram-Positive Bacterial Infections丨ECCMID 2023

Dr. José Luis Del Pozo: The Fight Against Gram-Positive Bacterial Infections丨ECCMID 2023

In an era where antibiotic-resistant infections like MRSA are on the rise, healthcare professionals are constantly in search of potent drugs to combat these pathogens. The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) presented an opportunity to explore advancements in this area. One of the notable voices at this congress was Dr. José Luis Del Pozo from the University of Navarra. Infectious Disease Frontline had a chance to sit down with him for a comprehensive discussion.
Antimicrobial Susceptibility Testing: Insights from EUCAST Pioneer, Dr. Gunnar Kahlmeter丨ECCMID 2023

Antimicrobial Susceptibility Testing: Insights from EUCAST Pioneer, Dr. Gunnar Kahlmeter丨ECCMID 2023

Antimicrobial susceptibility testing (AST) is critical in modern medicine, helping doctors determine which antibiotics are most likely to be effective against particular bacterial infections. Across the globe, standards for AST primarily revolve around the European EUCAST and the American CLSI. Dr. Gunnar Kahlmeter, one of the main architects of EUCAST, offers unique insights into the past, present, and future of AST.
Dr. Anne J. Gonzales-Luna: Progress in Pediatric Clostridioides difficile Infection丨ECCMID 2023a

Dr. Anne J. Gonzales-Luna: Progress in Pediatric Clostridioides difficile Infection丨ECCMID 2023a

Clostridioides difficile, a primary cause of antibiotic-associated diarrhea, presents a spectrum of clinical manifestations. While less prevalent in children than adults, the incidence of pediatric Clostridioides difficile infection (CDI) is on the rise. The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) dedicated a session to shed light on this pressing issue, with Dr. Anne J. Gonzales-Luna from the University of Houston College of Pharmacy offering her expertise.
Dr. Reena Rajasuriar: Eliminating Regional Disparities to Achieve the 2030 End of HIV Epidemic

Dr. Reena Rajasuriar: Eliminating Regional Disparities to Achieve the 2030 End of HIV Epidemic

Co-President of APACC 2023, Chief Researcher at the Center of Excellence for HIV/AIDS Research (CERiA) at the University of Malaya, Associate Professor at the Faculty of Medicine, University of Malaya, Research Fellow at the Peter Doherty Institute for Infection and Immunity, University of Melbourne. She is primarily responsible for the University of Malaya's HIV Immunology Translational Research Program, with her current research focus on the immunopathogenic mechanisms of aging in HIV/AIDS patients and their impact on patient health.
Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients

Honorary Dr. at the Amsterdam University Medical Center, University of Amsterdam, former President of the European AIDS Clinical Society (EACS) (2008-2012), former Regional Director for Europe and Central Asia on the Governing Council of the International AIDS Society (IAS) (2006-2014), Co-Chair of the 22nd International AIDS Conference (AIDS 2018), Director of the Netherlands HIV Monitoring Foundation, member of the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NAID) HIV Vaccine Data and Safety Monitoring Board, and member of various committees including CROI, EACS, and HIV Glasgow.
Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

Infectious Disease/HIV Specialist and Medical Professor at Monash University Alfred Hospital, Australia. Member of the Australian Antiretroviral Guidelines Committee and the International Antiviral Society-USA (IAS-USA) Antiretroviral Guidelines Panel. Leading and participating in the development of new antiretroviral drugs and the prevention and management of opportunistic infections, with a primary research focus on complications related to aging in HIV-infected individuals and their pathogenesis, prevention, and management.
Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT studies.
Dr. Heather-Marie Schmidt: WHO Long-Acting PrEP Guidelines and Priority Actions to End HIV Epidemic in Asia

Dr. Heather-Marie Schmidt: WHO Long-Acting PrEP Guidelines and Priority Actions to End HIV Epidemic in Asia

Dr. Schmidt serves as the Regional Advisor on HIV Testing, Prevention, and Key Populations for the Joint United Nations Programme on HIV/AIDS (UNAIDS) Asia-Pacific Regional Office and the World Health Organization (WHO) Global HIV, Hepatitis, and Sexually Transmitted Infections Program. She is dedicated to developing global guidelines for PrEP (Pre-Exposure Prophylaxis) and PEP (Post-Exposure Prophylaxis) and providing technical assistance to countries, organizations, and communities in the Asia-Pacific region to support the implementation and promotion of PrEP.
Dr. Dong Hsu: Meeting More Patient Needs in HIV Health Management

Dr. Dong Hsu: Meeting More Patient Needs in HIV Health Management

Implementation Science is a relatively new and increasingly recognized field of research. Its purpose is to translate the possibilities outlined in theory into practical applications in the real world, addressing the challenges of implementing validated intervention measures. At the 2023 APACC conference, Dr. Dong Hsu, from the School of Public Health Management and the Global Health Research Center, Southern Medical University, China, delivered an insightful presentation titled "Implementation of Clinical Practice Guidelines". In our interview, Dr. Dong Hsu further elaborated on the definition and research value of Implementation Science and shared his team's research findings in areas such as HIV screening and health management.
Dr. Steven Grinspoon: Statin Drugs Can Be Used for Primary Prevention of Cardiovascular Diseases in HIV-Infected Individuals

Dr. Steven Grinspoon: Statin Drugs Can Be Used for Primary Prevention of Cardiovascular Diseases in HIV-Infected Individuals

Chief of Metabolic Services at Massachusetts General Hospital (MGH), Director of Nutrition Obesity Research Center at Harvard University, and Honorary Chair of Endocrinology and Metabolism at MGH. Dr. Grinspoon led the large-scale, multi-center REPRIEVE study, which is the world's first research on primary prevention strategies for cardiovascular diseases in people living with HIV (PLWH).